Eisai Adds To Alzheimer's Arsenal With Anti-Tau Drug
It is a field littered with failures but Eisai remains hopeful that its pipeline of candidates for Alzheimer's disease, which has just been added to, gives the firm a number of shots at getting a disease-modifying agent to market.
You may also be interested in...
Roche’s neuroscience strategy of following the science, taking on lessons from open label extensions from Phase III studies, is vital to the success of gantenerumab, the company said in an interview with Scrip.
Emerging Company Profile: ADEL Inc. CEO Seung-Yong Yoon tells Scrip how its anti-tau antibody brings something different to the table in the challenging field of Alzheimer's disease and what's in store for the South Korean bioventure.
While other large biopharma companies are withdrawing from CNS research, Biogen is rare in not only staying in, but doubling down. Executives at the company’s 40th anniversary event in Switzerland explained why.